Why the study?
Amiodarone adverse reactions are severe and clinically apparent liver toxicity occurs in 1% of treated patients, necessitating increased awareness of prolonged jaundice secondary to use.
Amiodarone can cause prolonged jaundice and intrahepatic cholestasis even after discontinuation, highlighting the need for clinical awareness of this severe adverse effect.
Amiodarone may cause persistent cholestasis after discontinuation; case report leaves open incidence, risk factors, and management strategies.
Adverse reactions to the antiarrhythmic medication amiodarone are severe, potentially life-threatening, and not rare. One in three patients on long-term therapy experience elevated liver enzymes, and clinically apparent liver toxicity occurs in 1% of patients treated. We report the case of a 76-year-old patient with amiodarone-induced intrahepatic cholestasis and prolonged hyperbilirubinemia despite the discontinuation of the offending agent. Current research hypothesizes that amiodarone leads to hepatic injury both by direct hepatotoxicity and by increasing the likelihood of hepatocytes to create abnormal, toxic metabolites. Increased awareness of such an adverse effect can guide clinicians toward the possible underlying etiologies of prolonged jaundice.
No takes yet. Share an insight, caveat, or question.
Bratton et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: